Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: A method of creating spatiotemporal activity records for an education program may include determining a start of an activity. The method may additionally include tracking the activity to record at least one accomplishment or error achieved in the activity and at least one time/location indicator associated with the at least one accomplishment or error. The method may additionally include generating a spatiotemporal activity record that includes the at least one time/location indicator and the at least one accomplishment or error. The method may additionally include presenting at least a portion of the spatiotemporal activity record for review by a reviewer, receiving identification data of the reviewer as an indication that the reviewer has reviewed and understands the at least the portion of the spatiotemporal activity record, authenticating the reviewer as a service receiver, and verifying the spatiotemporal activity record as reviewed and approved by the service receiver.

Abstract: In one embodiment, a unified pointer message 300 may describe in a single type of pointer message a coordinate input from a user via multiple types of pointer devices. An input device interface 150 may receive a coordinate input 350 from an input device. A processor 120 may execute an application programming interface layer 430 that creates a unified pointer message 300 for the coordinate input 350. The processor 120 may send the unified pointer message 300 to an application. The processor 120 may process a device specific data set 244 unhandled by the application.

Abstract: A riveting tool including a magnet, a magnetically attractive housing, a non-magnetically attractive bucking bar received in the housing, the bucking bar being moveable relative to the housing along a bucking bar axis, and an actuation mechanism to move the bucking bar along the bucking bar axis.

Abstract: The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

Abstract: A method for dynamically configuring a video stream, including: identifying player control metadata attributes for an input video stream, wherein the input video stream is received from an origin server; storing the identified metadata attributes to a memory device; and dynamically inserting the metadata attributes into an output video stream in real-time.

Abstract: Method and apparatus for assembling, with fasteners, components of a structure having an outboard side, an inboard side, and a supporting frame. The components are placed together on the frame. An electromagnet having a core with multiple openings is positioned on the outboard side. A magnetically attractive member is placed against the inboard side opposite and aligned with the electromagnet. When activated, the electromagnet is attracted towards the magnetically attractive member and the two hold the components together. Multiple drill members pass through the openings in the core of the electromagnet and multiple openings are drilled simultaneously through the components. Subsequently, multiple rivets or huck bolts are simultaneously inserted into the drilled openings.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Abstract: Method and apparatus for assembling, with fasteners, components of a structure having an outboard side, an inboard side, and a supporting frame. The components are placed together on the frame. An electromagnet having a core with multiple openings is positioned on the outboard side. A magnetically attractive member is placed against the inboard side opposite and aligned with the electromagnet. When activated, the electromagnet is attracted towards the magnetically attractive member and the two hold the components together. Multiple drill members pass through the openings in the core of the electromagnet and multiple openings are drilled simultaneously through the components. Subsequently, multiple rivets or huck bolts are simultaneously inserted into the drilled openings. Finally, fasteners are hammered through the drilled openings and rivets are secured by bucking bars provided on the magnetically attractive member.

Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Abstract: A method may include receiving, from a network, a call request in a communication device, the call request including an identification of a calling party; notifying a user of the communication device of the call request; receiving an indication to deny the call request; prompting the user of the communication device, in response to receiving the indication to deny the call request, regarding automatically denying call requests having the identification of the calling party; receiving, from the user, an indication to deny call requests having the identification of the calling party; and sending an instruction to the network to automatically deny the call requests having the identification of the calling party.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: A method and apparatus for depositing a fluid over an interface. A nozzle may comprise a body having a first end and a second end, an input located at the first end of the body, an output located at the second end of the body, and a plurality of channels located within the body. The input may be configured to receive a fluid. The plurality of channels may have a configuration that causes the fluid received through the input to flow through the plurality of channels and exit the output to form a deposition having a desired shape over an interface.

Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.

Abstract: A system and method for allowing requests generated as a result of dynamic URLs to be efficiently looked up in a cache are provided. The system and method involve receiving a request for a content element, the request being generated from a dynamic URL. A static content element identifier is generated from the request. In an embodiment, the static content element identifier includes only the content identification parameters and the dynamic parameters are removed. The static content element identifier is then used to determine whether the content element is in the cache.

Abstract: The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.